Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

CAN1012 en OED, DCIS y LCIS.

21 de septiembre de 2026 actualizado por: Providence Health & Services

Un estudio de Fase I/Ib que evalúa el agonista TLR7 intralesional, CAN1012, en displasia epitelial oral, carcinoma ductal in situ y carcinoma lobulillar in situ

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This is not a dose finding study, and therefore patients may be enrolled to any of the four arms in any order, based on clinical considerations (e.g. OR scheduling). No arm, per specific disease type, may expand beyond the first 3 patients, until 30-day post-op safety evaluation has been completed. Study analysis is planned after a single dose of intralesional CAN1012.

The primary objective of this trial is to examine the safety of CAN1012 delivered by intralesional injection ahead of planned surgical resection. The study will be stopped early for patient safety according to stopping rules below. The sample size for the study is not based on any statistical assumptions. The number of subjects is based on the number of cohorts tested and the size of each cohort.

The Safety Analysis Set will consist of all subjects who receive at least one dose of study treatment. The Safety Analysis Set will be used for safety analyses.

The Intent-to-treat (ITT) Analysis Set will consist of all subjects who receive at least one dose of study treatment and have at least one post-Baseline assessment of tumor response.

The disposition of subjects will be summarized by presenting the number of subjects enrolled, the number and percentage of subjects in each analysis population, the number for whom the study drug was discontinued with the reasons for discontinuation, and the number of subjects who discontinued participation in the study with the reason(s) for withdrawal.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Oregon
      • Portland, Oregon, Estados Unidos, 97213
        • Reclutamiento
        • Providence Portland Cancer Institute - Franz Clinic
        • Sub-Investigador:
          • Rom Leidner, MD
        • Sub-Investigador:
          • Matthew Taylor, MD
        • Sub-Investigador:
          • David Page, MD
        • Sub-Investigador:
          • Alison Conlin, MD
        • Sub-Investigador:
          • Roxanne Griswold, NP
        • Sub-Investigador:
          • Rui Li, MD, PhD
        • Sub-Investigador:
          • RaYoung Chung, NP
        • Sub-Investigador:
          • Amy Hartman, NP
        • Sub-Investigador:
          • Molly Davis, NP
        • Sub-Investigador:
          • Brendan Curti, MD
        • Sub-Investigador:
          • Rachel Sanborn, MD
        • Contacto:
        • Investigador principal:
          • Sasha Stanton, MD, PhD
        • Sub-Investigador:
          • Mary Martel, NP
        • Sub-Investigador:
          • Jamie Martinez, NP
        • Sub-Investigador:
          • Binbin Zheng, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female patients with DCIS or LCIS found on core biopsy.

  2. Tumor types allowed:

    Biopsy-identified DCIS or LCIS comprising a single lesion ≥ 1 cm and ≤ 5 cm in size by imaging (mammogram or MRI or ultrasound (US)) without evidence of invasive disease on the biopsy and US negative for suspicious ipsilateral lymph nodes.

  3. Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.

  5. Laboratory values within 72 hours of Day 0:

    1. WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
    2. Hgb ≥ 10 g/dL
    3. Platelets ≥ 100,000 K/µL
    4. Creatinine Clearance (using Cockcroft-Gault) ≥ 60.
    5. AST/ALT ≤ 2.5 x ULN
    6. Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
    7. Negative pregnancy test for people of childbearing potential (bHCG urine or serum)
  6. Patients and their partners who are capable of conceiving must agree to use effective methods of contraception (non-hormonal only) during the course of treatment and for 165 days after last dose of CAN1012.

Exclusion Criteria:

  1. Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
  2. Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
  3. Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
  4. History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/hyperthyroidism are not exclusionary.
  5. Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
  6. Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
  7. Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
  8. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known history of Hepatitis C virus (defined as HCV RNA) infection. Testing for Hepatitis B and Hepatitis C is not required unless mandated by local health authority.
  9. Has a baseline electrocardiogram (ECG) with a prolonged QTc interval > 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
  10. Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm A: Day 2-3

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 2-3.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

Experimental: Arm B: Day 5-7

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 5-7.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

Experimental: Arm C: Day 9-11

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 9-11.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

Experimental: Arm D: Day 13-15

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 13-15.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety of CAN1012
Periodo de tiempo: Post-operative follow-up visit (30 days after surgery)

Safety will be measured by demonstrating that there is a less than 33% rate of delayed surgery attributable to the study treatment.

Post-operative follow-up visit (30 days after surgery)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Sasha Stanton, MD, PhD, Providence Health & Services

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de septiembre de 2026

Finalización primaria (Estimado)

1 de mayo de 2030

Finalización del estudio (Estimado)

1 de mayo de 2035

Fechas de registro del estudio

Enviado por primera vez

3 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de febrero de 2026

Publicado por primera vez (Actual)

13 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir